There is no doubt that real-world evidence studies have the potential to improve and accelerate the development and delivery of safe and cost-effective innovative medicines to patients as well as influence the way we approach health and health care. Realworld evidence studies are a great challenge in terms of development and conduct, so there should be a good collaboration between the study team and clinical sites at all times, resulting eventually in timely and efficient enrollment. Engaging the sites and key external experts as early as possible during feasibility and routine visits, as well as highlighting the science rationale behind AstraZeneca's portfolio at investigator meetings and during medical science liaison (MSL) interactions, can create a positive impact on physician perception of a particular study and prioritization of patient recruitment in such studies. Therefore, we would like to underline the important role of MSLs in the risk-based monitoring setting of real-world evidence studies, with special attention to the studies with complicated patient profiles, tough timelines, and/or seasonal factors. This approach will be used further for other real world evidence projects of AstraZeneca Russia MC to ensure timelines and budget deliverables are met for the generation of high-quality evidence and eventually better health care for all of us.
Introduction
Real-world evidence (RWE) studies are becoming an increasingly valuable component of both development and randomized clinical trial (RCT) scientific data analysis of pharmaceutic products. Detailed information on real-world effectiveness and safety is becoming a demand for the growing industry, impacting reimbursement and utilization of new products. Regulators, public and private payers, as well as prescribers are all seeking a better understanding of the impact of a new product in real-world settings, and RWE studies fit the purpose for all stakeholders. 1 As a result, RWE-based approaches are rapidly becoming the new standard and "business as usual" practice as a necessary tool for bringing a product to the health care market, ensuring its relevance in everyday practice and support throughout the product's life cycle. This is especially important for local markets because of regional or country diversity in routine health care. RWE studies, however, bring their own set of specific requirements with them, including, but not limited to, study design, approaches to data analysis, data quality, and sources and availability of information. 2 RWE studies can be conducted complementary to classic RCTs on a subset of data or can be completely independent studies. 3 When conducted as part of or as a follow-up to RCTs, RWE studies help pharmaceutical companies better recognize various aspects of medicine product use including effectiveness, safety, and tolerability in "real life" settings, as well as more detailed analysis of patients' treatment journey. On top of that, unlike RCTs, RWE protocols are less resource-and budget-intensive. The key benefits of real-world evidence studies are well defined for marketed products (including "newcomers"), as they give one an opportunity to translate readily available data produced in real time and in a costeffective fashion, into robust multidomain data on the true "value" of a medicine product relatively quickly and with minimal resource consumption, as opposed to lengthy and expensive late-phase RCTs. 4 Moreover, RWE-based data are getting increasingly valuable for reimbursement discussions with regulatory authorities as well as for market access discussions. Therefore, inclusion of RWE studies in the research and development program-either as stand-alone studies or in conjunction with clinical trials-is promising in terms of improvement of health outcomes and cost-effectiveness of new health technologies. The demand for RWE is growing and is unlikely to subside as health care decision makers become increasingly aware of what it can offer. Biopharmaceutical companies and clinical research organizations (CROs) need to stay at the forefront of development in RWE, including data sources, analytic techniques, and study methodologies, to ensure they are able to optimize patient access to and formulary placement of new products. 1 
Methods
In the Russian Federation, current legislation does not clearly define the terms for RWE studies and non-interventional studies; thus, pharmaceutical society and independent ethical committees establish and refine the rules of the RWE conduct through self-regulation. 5 Moreover, in the situation of vague rules and regulations, the quality of the non-interventional studies in Russia could be guaranteed almost only by pharmaceutical companies, acting in a sponsor's role and local ethics committees. Slightly aside are the studies initiated by investigators (investigator-initiated sponsor researches). In Russia, such studies are not widespread because of the lack of experience and awareness of the importance of transparency and quality control procedures. This allows a greater flexibility in RWE study setup but assumes good understanding of the peculiarities of RWE data collection and good therapeutic area knowledge at the same time.
Medical science liaisons (MSLs) work with key external experts (KEEs) as part of their daily routine and, therefore, can play a significant role in the process of KEEs' engagement in the proper collection of scientific evidence both for RCTs and for local RWE studies. 6, 7 Being focused on the ongoing provision of scientific and educational support as well as sites' identification strategy, MSLs build relationships within external (through collaboration with KEEs) and internal communities. MSLs' activities include but are not limited to consulting KEEs with regard to the proper collection of evidence for both RCTs and RWEs; building relationships with external and internal stakeholders (eg, health care professionals and researchers) and providing scientific and educational support; assisting in development, review, and follow-up of local RWE programs, including studies based on registries of patients, products, and diseases, database-related studies, and epidemiological surveys; assessing potential investigators and overall feasibility of clinical sites; supporting KEEs on pharmacovigilance including additional trainings, adverse events assessment, and checkup; and supporting drug safety updates for assigned products.
The traditional model for the conduct of RWE for AstraZeneca Russia assumes involvement of the contract research organization (CRO) with subsequent overall study tracking and quality control. However, we faced the necessity to revise this approach a bit to be in line with the study deliverables and budget key performance indicators (KPIs), especially given the risk-based approach to monitoring RWE studies and variety of data collected to build a reliable patient profile. A strong demand for the reliable estimate of study costs and duration (including recruitment/data collection timelines), as well as for robust follow-up, quality control, and publication strategy, assumes that AstraZeneca needs to involve more internal resources to make the process of running an RWE study manageable and better controlled. Under these circumstances, we increased the number and duties of the MSLs. Because of the size of Russia, an MSL network from Saint-Petersburg to the Far East, consisting of more than 45 MSLs for all therapeutic areas, was created in 2014-2016. The structure of MSL networks together with the uncertainty in legislation seems to be the key point that differentiates the processes of NIS studies in AstraZeneca Russia from other marketing companies in AstraZeneca.
Results and Discussion
Hereby, we would like to share the experience of MSLs' involvement in 2 key processes for RWE studies: site feasibility assessment and ongoing enrollment control. In order to gain control over these 2 key deliverables, a local model of interaction between MSL and CRO staff was elaborated and implemented, including development of a special questionnaire for MSLs as well as a regular internal check of sites and investigators participating in RWE studies. Communication is essential in the successful recruitment of patients in any clinical or observational studies, and these RWEs proved this statement very well. Engaging sites and KEEs early during feasibility and routine visits, as well as highlighting the scientific rationale behind AstraZeneca's portfolio at investigator meetings and MSL interactions, had a highly positive impact eventually on physicians' perception of the study rationale and, as a consequence, prioritization of patient recruitment for these local studies.
PREVENT study (ClinicalTrials.Gov ID: NCT02155998) was targeted at the population of adult male patients with locally advanced prostate cancer with high and very high risk of recurrence who had undergone surgery or radiotherapy within 3 months prior to enrollment, consented to participate in this non-interventional study, and who were being treated for prostate cancer in the oncology institutions/departments in Russian Federation. Observational studies in oncology are generally recognized as problematic, 8 and on top of this, inclusion criteria in this particular study were quite tough (required prostate cancer risk stratification). As a result, we faced delayed recruitment and the urgent need to undertake additional steps. By the time of implementation of the new strategy, 7 months after the first subject inclusion, there were only 34 patients recruited at 8 active sites, while the overall target recruitment was 200 patients from 20 centers. Introduction of the active collaboration between MSLs and low enrolling centers resulted in the recruitment of an additional 83 patients, which was achieved in 3 months, with the final enrollment reaching 203 patients. Figure 1 shows the average enrollment rate during the first 7 months as well as after the decision on active MSLs involvement was made.
For the second study, SUPPORT (ClinicalTrials.Gov ID: NCT02248909), the study objectives included evaluation and justification of the value of spirometry as a method of diagnostics for patients with COPD risk factors as well as data collection regarding the distribution of COPD patients by obstruction severity and exacerbation risk degrees using GOLD criteria 2014. 9 Target population were the patients with COPD risk factors and patients with previously diagnosed COPD who have been observed in outpatient medical institutions in the Russian Federation. In this RWE study, involvement of MSLs led to a 48% increase of the study subjects' enrollment rate (patients per week per site) that resulted in 4232 patients in 35 study sites (2756 patients with COPD risk factors and 1476 patients with established COPD diagnosis). The average enrollment rate during the first 4 months was 122 patients per week, while during the 2 months after MSL input, there was an increase of up to 231 patients per week. Figures 2 and 3 show the comparison of the enrollment rate and overall enrollment before and after the inclusion of MSL in study activities. SUP-PORT study results were a breakthrough in RWE studies of COPD in the Russian Federation and were presented at the American Thoracic Society International Conference in 2016. 10 Based on the positive experience in PREVENT and SUP-PORT studies, the MSL team took active part in communication with the study sites in the CLOUD study (ClinicalTrials.Gov ID: NCT02346292), started in April 2015, dedicated to the description of COPD exacerbations registered in inpatient departments of pulmonology or therapy.
During the 9-month enrollment period, the average recruitment speed was ever increasing and led to the enrollment of an extra 10% patients compared to the original target (see Figure  4) . It is important to note that the enrollment rate was stable and exceeded our expectations even during the summer period, which is generally well known for the low investigator activity (see Figure 5 ). Substantial increase and maintenance of high recruitment rates was supported by MSLs who, during the active recruitment phase of all studies, had a set of visits to investigators to update sites on the study status information as well as to collect feedback and progress reports. In order to improve MSLs' communication with regional KEEs and CRO staff during the conduct of local RWE studies, a special questionnaire was developed as one the instruments for the feasibility assessment, ongoing review, and quality control of study conduct (Table 1) .
RWE studies could facilitate and bridge closer cooperation between health care professionals, especially regional ones, and pharmaceutical companies based on concepts of scientific cooperation and leadership. The role of the regional medical team in such projects proved to be rather significant and could be proposed as one of the qualitative and/or quantitative metrics for the assessment of MSL performance.
Having unique access to a continuously updated understanding of the changing needs of physicians and patients, Medical Affairs and MSLs, as their regional representatives, can and must play a central role as a facilitator that brings the scientific voice to guide the development and conduct of RCTs and/or RWE studies. Moreover, as a facilitator, it is critical that Medical Affairs develop one unified voice on the value proposition to patients, providers, and payers. At the same time, it is important for Medical Affairs to reestablish the pharmaceutical company's integrity and credibility by communicating higher-quality medical information that is of the highest relevance to customers. It should aspire to the greatest data transparency (eg, providing access to patient-level clinical trial data) in order to gain recognition as an unbiased source of medical information.
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Conclusions
MSLs' value could be further increased and quantified through the participation in RWE studies. MSLs must be a part of sponsor's study team for every multicenter (>20 sites) non-interventional study and be involved in regular contacts with the sites and engagement of key external experts. MSLs can supply a valuable information regarding the preferred sites to be included in the feasibility list for the CRO or company clinical department. Routine MSL visit to a clinical site should include topics in the agenda related to any ongoing non-interventional studies (questions related to scientific matter, enrollment rate, protocol, case report form, etc). Special MSL questionnaire and regular monitoring approach were developed and implemented for RWE studies conducted by AstraZeneca Russia. CRO monitoring and QA activities must be harmonized with the MSLs' visit schedule to increase efficiency. MSLs can play an important role in protocol-specific adverse event reporting trainings and actualization of importance of pharmacovigilance processes.
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